Canopy and Willamette Valley Cancer Institute and Research Center Announce Partnership to Improve Care Between Visits

WVCI to leverage Canopy's best-in-class AI across patient services to improve care between visits for patients and staff

Canopy, the leader in Enterprise AI for oncology, today announced a partnership with Willamette Valley Cancer Institute and Research Center (WVCI), a leader in advanced cancer treatments for over 25 years, to improve care between visits for both patients and staff.

"We continuously evaluate technology solutions to help us provide better care for our patients while lowering the administrative burden for our staff. With Canopy, we’re leveraging best-in-class AI across patient services to achieve this, particularly through remote therapeutic monitoring."

—Casey Chiasson, MBA, Executive Director of Willamette Valley Cancer Institute and Research Center

Canopy helps practices manage the growing complexity of cancer care by providing a single Enterprise AI platform across patient services: triage, call center, referrals, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture reimbursement to sustain between-visit care through Principal & Chronic Care Management (PCM/CCM), Remote Therapeutic Monitoring (RTM), and more.

"WVCI has built a strong reputation as a leader in research and innovation. We’re proud to advance their mission through technology that enhances efficiency, reduces administrative burden, and delivers innovative solutions such as remote therapeutic monitoring."

—Lavi Kwiatkowsky, Founder and CEO of Canopy

Presentations highlighting the potential impact of Canopy’s platform on oncology patient experience in real-world settings have demonstrated:

• 37% reduction in treatment discontinuation at three months¹ [ASH, 2024]

• 22% - 45% improvement in treatment persistence at three months² [ASCO, 2022]

• 22% reduction in ER visits/hospitalizations per 100 patient months³ [ASCO, 2022]

• 88% sustained patient engagement sustained at six months⁴ [JCO, 2022]

• Improved early detection of toxicities with bispecific antibody therapies⁵ [ASH, 2024]

Care teams using Canopy have also seen:

• 15-minute average resolution time for patient symptom reports⁶

• 93% faster resolution of all patient requests compared to prior workflows⁶ 

Canopy is contracted with 10% of oncology providers in the U.S. and rapidly growing.

About Canopy

Canopy is Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.us.

About Willamette Valley Cancer Institute and Research Center

The Willamette Valley Cancer Institute and Research Center has been a leader in advanced cancer treatments for over 25 years, serving the Willamette Valley and surrounding regions including Albany, Corvallis, Eugene, Florence, Lincoln City, Newport, and Springfield, Oregon. WVCI is committed to offering innovative and integrated care, backed by cutting-edge technology and extensive clinical research. Learn more at https://www.oregoncancer.com/.

Media Contact:
Kaitlin Hemric

Learn More

Interested in learning more? Contact our team using the button below.

1. Essell, J. H., Derman, B. A., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 8). Symptoms detection among patients with lymphoid malignancies (LM) using electronic patient-reported outcomes (ePROs) in community hematology-oncology clinics. American Society of Hematology Annual Meeting
2. Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528
3. Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508
4. Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180
5. Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting
6. Canopy internal analysis of partnership data